L immunology oncology

Question 1

Antibody producing cells:
A. T cells
B. NK cells
C. B cells
D. Gay cells

Answer 1

C. B cells

Question 2

Fully human
A. -o
B. -xi
C. -zu
D. -u

Answer 2

D

Question 3

Humanized
A. -o
B. -xi
C. -zu
D. -u

Answer 3

C

Question 4

Mouse
A. -o
B. -xi
C. -zu
D. -u

Answer 4

A

Question 5

Chimeric
A. -o
B. -xi
C. -zu
D. -u

Answer 5

B

Question 6

T or F:
HER2 is genomically amplified in breast cancer

Answer 6

True

Question 7

Trastuzumab more commonly known name

Answer 7

herceptin

Question 8

Trastuzumab is a recombinant _________ mab specific for ____

Answer 8

humanized
HER2

Question 9

Trastuzumab binds to receptor and induces antibody-dependent cellular _______

Answer 9

cytotoxicity

Question 10

primary indication of trastuzumab

Answer 10

breast cancers that overexpress HER2

Question 11

4 toxicities listed under trastuzumab

Answer 11

flu like sxs
risk of cardiomyopathy/CHF
increase in myelosuppression
hypersensitivity rxs

Question 12

Pertuzumab binds to her2 and inhibits ______***

Answer 12

dimerization (which also inhibits kinase activity)

Question 13

T or F:
Pertuzumab and Trastuzumab are used in combination

Answer 13

True

Question 14

what was the significance of the CLEOPATRA trial?

Answer 14

using both antibodies (pertuz and trastuz) against HER2 increased efficacy

Question 15

what does margetuximab target

Answer 15

HER2

Question 16

Cetuximab class

Answer 16

EGFR antibody

Question 17

Cetuximab binds specifically to what

Answer 17

extracellular domain of the EGF receptor

Question 18

T or F:
Cetuximab is a competitive inhibitor

Answer 18

true

Question 19

Cetuximab competitively inhibits binding of ____ and ____

Answer 19

EGF
TGF-alpha

Question 20

T or F:
Cetuximab blocks phosphorylation and activation of receptor-associated kinases **

Answer 20

true

Question 21

primary indication of Cetuximab

Answer 21

tx of colorectal and head and neck cancers

Question 22

big all caps thing under toxicities for cetuximab

Answer 22

severe infusion reaction in ~3% of patients - usually first dose if that matters

Question 23

T or F:
Panitumumab is fully humanized

Answer 23

true

Question 24

where does panitumumab bind?

Answer 24

extracellular domain of the EGF receptor

Question 25

primary indication of panitumumab

Answer 25

tx of colorectal cancer

Question 26

T or F: Panitumumab carries the same infusion toxicities as cetuximab

Answer 26

false, it dont

Question 27

Bevacizumab is specific for ?

Answer 27

VEGF

Question 28

What is the significance of Bevacizumab binding VEGF?

Answer 28

It blocks endothelial cell proliferation and new blood vessel formation

Question 29

T or F: There is no evidence of efficacy of Bevacizumab as a single agent

Answer 29

true

Question 30

Bevacizumab is used in combo with ______ based chemotherapy for 1st line tx of metastatic colorectal cancer

Answer 30

5-FU

Question 31

Binds VEGF: A. Bevacizumab B. Ramucirumab

Answer 31

A

Question 32

binds VEGFR A. Bevacizumab B. Ramucirumab

Answer 32

B

Question 33

Which of the following antibodies targets Her2? A. Neratinib B. Cetuximab C. Lapatinib D. Pertuzumab

Answer 33

D

Question 34

What was the first immunotherapy? A. Pertuzumab B. Keytruda C. Coley’s toxin D. Trastuzumab

Answer 34

my toxin

Question 35

The antibody Fakeumab has just entered the market. What type of the antibody was it? A. Fully human B. Humanized C. Fully mouse D. Chimeric

Answer 35

a

Question 36

T or F: CD20 works with B-cell receptor to drive proliferation of B-cells

Answer 36

true

Question 37

T or F: CD20 plays a role in the proliferation of B-cell lymphomas

Answer 37

true

Question 38

Rituximab is a _____ antibody

Answer 38

CD20

Question 39

what does rituximab bind to?

Answer 39

CD20

Question 40

Ofatumumab is a ________ antibody specific for _____ originally developed to treat multiple sclerosis and now used in CLL

Answer 40

fully human monoclonal CD20

Question 41

Rituximab and Obinutuzumab are currently approved for what?

Answer 41

B-cell lymphomas (non-hodgkins lymphoma) that target different binding sites on CD20

Question 42

Daratumumab target

Answer 42

CD38

Question 43

Multiple myeloma is a cancer of __________ plasma cells

Answer 43

malignant

Question 44

CD38 is found on ______ cells that do not have _____ on their surface

Answer 44

plasma CD20

Question 45

T or F: Daratumumab also eliminates NK cells

Answer 45

true

Question 46

antibody drug-conjugates both have which drug involved

Answer 46

trastuzumab

Question 47

Trastuzumab Emtansine (TDM1) binds to what? What does this lead to?

Answer 47

HER2/Neu receptor usual herceptin response

Question 48

T or F: Emtansine is a cytotoxic agent

Answer 48

true

Question 48

Emtansine enters cells and _______ microtubule assembly

Answer 48

inhibits

Question 49

trastuzumab emtansine is approved for what

Answer 49

as a 2nd line tx for HER2-positive metastatic breast cancer

Question 50

3 toxicities listed under trastuzumab emtansine

Answer 50

- adverse effects of trastuzumab - thrombocytopenia (mertansine) - Hepatotoxicity (mertansine)

Question 51

Another ADC is trastuzumab-deruxtecan. what class is deruxtecan?

Answer 51

TOPO I inhibitor

Question 52

negative selection of T-cells that bind to "self" peptides in the thymus: A. central tolerance B. peripheral tolerance

Answer 52

A central

Question 53

self reactive t cells that escape the thymus and are inactivated to an unresponsive state by Tregs or fail to be properly stimulated by APCs A. central tolerance B. peripheral tolerance

Answer 53

B

Question 54

where is central t-cell tolerance occuring?

Answer 54

thymus

Question 55

taking a break here